Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts

Group 1 - Adma Biologics (ADMA) closed at $18.26, reflecting a +1.44% change from the previous day, outperforming the S&P 500's loss of 0.3% [1] - Over the past month, ADMA shares have decreased by 1.15%, underperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of $0.14, representing a 7.69% increase from the same quarter last year, with quarterly revenue expected to be $121.1 million, up 12.98% year-over-year [2] - Full-year Zacks Consensus Estimates predict earnings of $0.61 per share and revenue of $505.8 million, indicating year-over-year changes of +24.49% and +18.61%, respectively [3] Group 3 - Recent modifications to analyst estimates for Adma Biologics reflect short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [4] - The Zacks Rank system, which integrates estimate changes, currently ranks Adma Biologics at 4 (Sell), with the consensus EPS estimate remaining unchanged over the past month [5][6] Group 4 - Adma Biologics has a Forward P/E ratio of 29.51, which is higher than the industry average of 20.15, suggesting that the company is trading at a premium [7] - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [7][8]